Phase 2/3 trial of VY-AADC01 in the patients with advanced Parkinson's disease
Phase of Trial: Phase II/III
Latest Information Update: 23 Jan 2018
At a glance
- Drugs AAV-hAADC (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Voyager Therapeutics
- 23 Jan 2018 According to a Voyager Therapeutics media release, the US FDA has cleared the Investigational New Drug (IND) application for VY-AADC.
- 30 Oct 2017 According to a voyager Therapeutics media release, the company plans to dose the first patient during the second quarter of 2018.
- 12 Sep 2017 New trial record